Know Your Biomarker: Tumor Sidedness
Over the last several months, the Global Colon Cancer Association has presented a patient education campaign on Tumor Sidedness as part of our Know Your Biomarker program. Through a series of blog posts, web content, animated social media infographics, and a fact sheet and healthcare provider discussion guide, we have examined the demographic and biological differences between right-sided and left-sided colorectal cancer, including molecular, genetic, and clinical distinctions. We have explored why tumor sidedness matters, covering prognosis and treatment implications, and we’ve focused on targeted therapies, chemotherapy, and personalized approaches to treatment based on tumor location.
If you or a loved one has been diagnosed with colorectal cancer, here are the key takeaways:
- Ask about tumor sidedness: Make sure your pathology report includes the specific location of your tumor and discuss with your healthcare provider whether it's classified as right-sided or left-sided.
- Understand it's one piece of the puzzle: Tumor sidedness is important, but it's just one of several biomarkers your medical team will consider. Other factors like RAS/BRAF mutation status, MSI status, and overall health all contribute to treatment decisions.
- Treatment is personalized: Your treatment plan should be tailored to your specific tumor's characteristics, including its location, molecular profile, and stage.
- Stay informed: As research continues, our understanding of how to best treat different types of colorectal cancer continues to evolve. Stay engaged with your care team and ask questions.
- Advocate for comprehensive testing: Ensure you receive complete biomarker testing, including tumor sidedness, MSI status, and genetic mutations, to guide the most effective treatment approach.
Knowledge is critical in managing colorectal cancer. By understanding tumor sidedness and advocating for comprehensive biomarker testing, patients and families can be active participants in making informed treatment decisions alongside their healthcare teams.
The Tumor Sidedness campaign, part of the Know Your Biomarker program, was made possible with support from Amgen.